Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/2065

Title: Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals
Authors: Collette, L
Carroll, KJ
Newling, D
Morris, T
Schroder, FH
Issue Date: 2005
Citation: JOURNAL OF CLINICAL ONCOLOGY, 23(25). p. 6139-6148
Abstract: Purpose The long duration of phase III clinical trials of overall survival (OS) slows down the treatment-development process. It could be shortened by using surrogate end points. Prostate-specific antigen (PSA) is the most studied biomarker in prostate cancer (PCa). This study attempts to validate PSA end points as surrogates for OS in advanced PCa. Patients and Methods 161 advanced PCa patients treated in studies comparing bicalutamide Individual data from 2, to castration were used in a meta-analytic approach to surrogate end-point validation. PSA response, PSA normalization, time to PSA progression, and longitudinal PSA measurements were considered. Results The known association between PSA and OS at the individual patient level was confirmed. The association between the effect of intervention on any PSA end point and on OS was generally low (determination coefficient, < 0.69). Conclusion It is a common misconception that high correlation between biomarkers and true end point justify the use of the former as surrogates. To statistically validate surrogate end points, a high correlation between the treatment effects on the surrogate and true end point needs to be established across groups of patients treated with two alternative interventions. The levels of association observed in this study indicate that the effect of hormonal treatment on OS cannot be predicted with a high degree of precision from observed treatment effects on PSA end points, and thus statistical validity is unproven. In practice, non-null treatment effects on OS can be predicted only from precisely estimated large effects on time to PSA progression (TTPP; hazard ratio, < 0.50).
Notes: European Org Res Treatment Canc, Ctr Data, B-1200 Brussels, Belgium. Limburgs Univ Ctr, Diepenbeek, Belgium. AstraZeneca Pharmaceut, Macclesfield, Cheshire, England. Erasmus Univ, Med Ctr, Rotterdam, Netherlands.Collette, L, European Org Res Treatment Canc, Ctr Data, Ave Emmanuel Mounier 83-11, B-1200 Brussels, Belgium.laurence.collette@eortc.be
URI: http://hdl.handle.net/1942/2065
DOI: 10.1200/JCO.2005.08.156
ISI #: 000231606300039
ISSN: 0732-183X
Category: A1
Type: Journal Contribution
Validation: ecoom, 2006
Appears in Collections: Research publications

Files in This Item:

There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.